Prospective Evaluation of Chondroitin Sulfate, Heparan Sulfate and Hyaluronic Acid in Prostate Cancer.

Int Braz J Urol 2018 Nov-Dec;44(6):1139-1146

Departamento de Bioquímica, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brasil.

Purpose: The present study evaluates chondroitin sulfate (CS) and heparan sulfate (HS) in the urine and hyaluronic acid (HA) in the plasma of patients with prostate cancer before and after treatment compared to a control group.

Materials And Methods: Plasma samples were used for HA dosage and urine for quantification of CS and HS from forty-four cancer patients and fourteen controls. Clinical, laboratory and radiological information were correlated with glycosaminoglycan quantification by statistical analysis.

Results: Serum HA was significantly increased in cancer patients (39.68 ± 30.00 ng/ mL) compared to control group (15.04 ± 7.11 ng/mL; p=0.004) and was further increased in high-risk prostate cancer patients when compared to lower risk patients (p = 0.0214). Also, surgically treated individuals had a significant decrease in seric levels of heparan sulfate after surgical treatment, 31.05 ± 21.01 μg/mL (before surgery) and 23.14 ± 11.1 μg/mL (after surgery; p=0.029). There was no difference in the urinary CS and HS between prostate cancer patients and control group. Urinary CS in cancer patients was 27.32 ± 25.99 μg/mg creatinine while in the men unaffected by cancer it was 31.37 ± 28.37 μg/mg creatinine (p=0.4768). Urinary HS was 39.58 ± 32.81 μg/ mg creatinine and 35.29 ± 28.11 μg/mg creatinine, respectively, in cancer patients and control group (p=0.6252).

Conclusions: Serum HA may be a useful biomarker for the diagnosis and prognosis of prostate cancer. However, urinary CS and HS did not altered in the present evaluation. Further studies are necessary to confirm these preliminary findings.

Download full-text PDF

Source
http://dx.doi.org/10.1590/S1677-5538.IBJU.2017.0569DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442162PMC
February 2019

Publication Analysis

Top Keywords

cancer patients
24
prostate cancer
20
μg/mg creatinine
12
heparan sulfate
12
control group
12
cancer
10
patients control
8
hyaluronic acid
8
sulfate heparan
8
μg/ml surgery
8
compared control
8
chondroitin sulfate
8
patients
8
prostate
5
sulfate
5
urinary prostate
4
3105 2101
4
treatment 3105
4
sulfate surgical
4
surgical treatment
4

References

(Supplied by CrossRef)
Prostate cancer: promising biomarkers related to aggressive disease
Ribeiro da Silva MN et al.
Actas Urol Esp 2012
Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels
Adany R et al.
J Biol Chem 1990
Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer
Posey JT et al.
Cancer Res 2003

Similar Publications